NasdaqGM:HROWPharmaceuticals
Can New Retina Data Deepen Harrow’s (HROW) Moat In Ophthalmology Or Just Refine Its Story?
Harrow recently highlighted three new clinical and real-world studies for its retina portfolio at the 2026 ASRS Annual Meeting, including interim randomized data and a nearly 20,000‑injection safety analysis for IHEEZO, plus interim post‑marketing findings for BYOOVIZ from Samsung Bioepis.
The early signals of improved post‑injection patient experience with IHEEZO, alongside large‑scale safety data and expanding evidence for BYOOVIZ, strengthen the clinical underpinnings of Harrow’s retina...